(Oslo, 7 May 2021)
Icepharma new distributor of antibiotics to the Icelandic market
Navamedic ASA (“Navamedic”, OSE: NAVA) announces it has signed an agreement with Icepharma for distribution of the antibiotics products to the Icelandic market.
As announced on 4 August 2020, Navamedic completed the acquisition of marketing authorisations in the Nordics for a portfolio of antibiotics products. The antibiotics in the portfolio, now fully onboarded on Navamedic’s platform, are designed to be given intravenously to patients and are in regular use in hospitals in all the Nordic countries.
In accordance with the plan to roll out antibiotics in the Nordic region, Navamedic has signed an agreement with Icepharma for distribution of the antibiotics products to the Icelandic market.
“The addition of the antibiotics portfolio marked an important milestone for Navamedic and our expanding hospital and prescription drug offering. We are pleased to welcome Icepharma to join us in securing steady supply of these important products to Nordic hospitals,” says Kathrine Gamborg Andreassen, CEO of Navamedic.
The antibiotics in the portfolio are designed to be given intravenously to patients and are currently in regular use in hospitals in all the Nordic countries with an annual turnover of approximately NOK 25 million. This portfolio will strengthen Navamedic´s hospital offering with an important product range. This is an important step in Navamedic´s growth strategy.
Navamedic has recruited Janne Folmoe to the company’s Specialty Pharma commercial team. Folmoe comes with extensive experience from the ACS Dobfar portfolio with focus on tender management, and previous commercial positions in the pharma industry in companies such as Bayer and Mylan. Folmoe will play a key role in the commercial operation with regards to the antibiotics portfolio.
For more information, please contact:
Kathrine Gamborg Andreassen, CEO of Navamedic ASA
Alexander Lidmejer, Commercial Director Specialty Pharma at Navamedic ASA
+46 70 257 99 71
Navamedic ASA is a Nordic pharma company and reliable provider of high-quality products, delivered to hospitals and through pharmacies, meeting the specific needs of patients and consumers by leveraging its highly scalable market access platform, leading category competence and local knowledge. Navamedic is present in all the Nordic countries, the Baltics and Benelux, with sales representation in the UK and Greece. Navamedic is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange (ticker: NAVA). For more information, please visit www.navamedic.com